Literature DB >> 18328984

Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders.

Stuart H Ralston1.   

Abstract

Several rare inherited osteolytic disorders have been described that show phenotypic overlap with Paget's disease of bone (PDB). Familial expansile osteolysis, early-onset familial PDB and expansile skeletal hyperphosphatasia are related disorders caused by mutations affecting the TNFRSF11A gene, which encodes the receptor activator of NFkappaB (RANK). The mutations result in failure of normal processing of RANK and osteoclast activation. Inactivating mutations in the TNFRSF11B gene, which encodes osteoprotegerin, cause idiopathic hyperphosphatasia which is a severe disorder that shares phenotypic similarities with PDB. The syndrome of hereditary inclusion body myopathy, PDB and frontotemporal dementia is caused by mutations in the gene encoding for valosin-containing protein which is involved in regulating degradation of ubiquitinated proteins. Anecdotal reports indicate that osteoclast inhibitors such as bisphosphonates are effective for suppressing bone turnover and improving symptoms in these disorders, although the long-term effects on clinical outcomes are unclear.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18328984     DOI: 10.1016/j.berh.2007.11.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  7 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Ioannis Litsas; Zoe Efstathiadou; Marina Kita; Georgios Arsos; Efstratios Moralidis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2010-06-09       Impact factor: 2.626

Review 3.  Denosumab: an Emerging Therapy in Pediatric Bone Disorders.

Authors:  Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

4.  Polymorphisms of CSF1 and TM7SF4 genes in a case of mild juvenile Paget's disease found using next-generation sequencing.

Authors:  Judit Donáth; Gábor Speer; János P Kósa; Kristóf Árvai; Bernadett Balla; Péter Juhász; Péter Lakatos; Gyula Poór
Journal:  Croat Med J       Date:  2015-04       Impact factor: 1.351

Review 5.  The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment.

Authors:  Stefano Stagi; Loredana Cavalli; Salvatore Seminara; Maurizio de Martino; Maria Luisa Brandi
Journal:  Ital J Pediatr       Date:  2014-06-07       Impact factor: 2.638

6.  Intermediate Type of Juvenile Paget's Disease: A Rare Case in Indian Population.

Authors:  S Ravi Raja Kumar; Bhavana S Bagalad; Ch Balakrishna Manohar; Puneeth H Kuberappa
Journal:  Contemp Clin Dent       Date:  2017 Jan-Mar

Review 7.  Genetic approaches to metabolic bone diseases.

Authors:  Fadil M Hannan; Paul J Newey; Michael P Whyte; Rajesh V Thakker
Journal:  Br J Clin Pharmacol       Date:  2018-11-28       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.